OCUMENSION-B

Following the NMPA approval of OT-401 (fluocinolone acetonide intravitreal implant for uveitis) and the successful Phase III trial outcome for OT-101 (myopia correction drug) in recent weeks, Ocumension's share price rallied 7-8% in preceding sessions before encountering profit-taking pressure today, reverting some gains. The stock remains deeply pressured year-to-date, down 36.09% since the beginning of 2026 and trading 46.03% below the 52-week high of HKD 8.94. On fundamentals, H1 2026 operating revenue reached HKD 244.7 million with solid year-over-year growth of 51.9%, yet net loss expanded to -HKD 57.2 million with an unchanged negative net margin of -23.37%, signaling the company remains in a capital-intensive R&D phase with profitability still on the horizon.

Ocumension fell 4.39% to HKD 4.35 today, mainly driven by profit-taking following recent positive catalysts from its pipeline. The company announced that its Phase III trial of myopia drug OT-101 hit its primary endpoint in the China cohort—a significant development—yet market enthusiasm remained muted. Financially, H1 FY26 showed a combined operating revenue of HKD 485 million with year-over-year growth of approximately 44-52%, while net losses narrowed 21.12% to HKD 57.2 million, signaling early commercialization traction. Price-wise, the stock trades 51.34% below its 52-week high of HKD 8.94, down 42.38% year-to-date, currently below both its 20-day (4.929) and 60-day (5.165) moving averages—a substantially depressed valuation. That said, the company remains in a loss-making phase with intense competition in ophthalmology, leaving commercialization prospects uncertain.

Ocumension Therapeutics declined over 5% to close at HK$4.555 today in a pullback that began with the opening price of HK$4.770 and extended throughout the session, with consistent selling pressure from morning through close. The company has recently released multiple positive pipeline updates: OT-101 myopia drug achieved its primary endpoint in a China Phase III trial, while OT-301 glaucoma and OT-502 postoperative inflammation products won regulatory acceptances from China's NMPA, yet markets appear to be consolidating after digesting these near-term catalysts. On the fundamental side, H1 revenue of HK$241-245 million grew 51.9%-52.83% year-over-year, driven by eye-care drug commercialization, though net losses persisted at HK$56-57 million with a net margin of -23.37%, signaling the company remains distant from profitability. Regarding valuation metrics, the stock is down 49.05% from its 52-week high of HK$8.94, has fallen 39.67% year-to-date, currently trades below its 20-day moving average of HK$5.029, and carries a price-to-book ratio of 0.89x at lower valuation levels. The company's market capitalization stands at approximately HK$3.71 billion.

Ocumension Therapeutics slipped 2.83% to HKD 4.800, with the afternoon session reversing morning gains near HKD 4.93. Despite encouraging pipeline progress—OT-101 myopia Phase III achieving primary endpoints in China patient cohort, OT-301 glaucoma NDA accepted by NMPA, OT-211 dry eye completing enrollment—the market responded with indifference, possibly reflecting a 'sell-the-news' mentality. On the financial front, H1 revenue grew 51.9%-52.83% YoY to HKD 244.7M-240.8M, with net loss narrowing to roughly RMB 99M, demonstrating scalability momentum; however, a -23.37% net margin and negative EPS persist, signaling profitability validation remains pending. Technically, shares have declined 36.42% since year-start from HKD 7.55 and now trade 46.31% below the 52-week peak of HKD 8.94, materially below MA60 (5.216), yet the thin 2% turnover suggests the market views the stock as 'cheap but uncompelling.' Goldman Sachs' reiteration of Hold further underscores institutional caution on risk-reward balance.

Ocumension Biopharma declined roughly 2% to 4.86 HKD today, primarily driven by profit-taking after recent regulatory acceptance of glaucoma drug OT-301 by China's NMPA. Despite strong revenue growth of 51.9% year-over-year to HKD 245 million in Q2 and losses narrowing by over 20%, the company faces competitive pressure from Nicox's simultaneous advancement of NCX 470 and other rivals, creating market divergence on new drug commercialization prospects. From a valuation perspective, the stock has retreated 46% from its 52-week high of HKD 9.01, approaching the 52-week low of HKD 4.04, while maintaining a negative net margin of -23.4% and price-to-book ratio of only 0.95x, suggesting the market remains cautious on profitability. The afternoon session saw a temporary dip to 4.73 HKD before partial recovery.